CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The PR22 (ANZUP 1801) study DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate. A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer has been centrally activated in Canada.
CCTG would like to extend congratulations to Dr. Kelvin Chan the recipient of the 2020 Dr. Maurice McGregor Award from Canadian Agency for Drugs and Technologies in Health (CADTH). The Dr. Maurice McGregor Award, honours rising stars early in their careers.
Congratulations to our CCTG Hematologic Disease Site Chair, Dr. Tony Reiman, who has been successfully reappointed as the Canadian Cancer Society Research Chair at the University of New Brunswick.
Great news to share from the CCTG IC8 trial team! The study already has 6 sites currently participating with 29 patients accrued. Congrats to all of the trial teams at:
The CCTG Pharmacy Network is actively seeking pharmacy representation for the Genitourinary Disease Site Committee and the Steering Group - Quebec.
The Canadian Cancer Society (CCS) is seeking your input on the development of a new CCS Research Strategy. As a cancer researcher, CCS is interested in your thoughts about the values, challenges, strengths, and opportunities related to cancer research. This input will inform CCS's cancer research strategy development so that we can be as relevant, supportive and effective as possible with our research funding.
The Canadian Cancer Society Awards for Excellence in Cancer Research recognize individuals who have made, and are making, valuable contributions to the cancer research ecosystem in Canada. Recipients are leaders in their fields who exemplify excellence in science and outstanding service to the scientific community. There are two new awards this year find out more here.
